Locked Dimerized CXCL12 Exerts Radiosensitizing Effects in Head and Neck Cancer
Authors:
- 26 December 2024
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 47 (5) , 1379-1391
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) presents significant treatment challenges, particularly in cases unrelated to human papillomavirus (HPV). The chemokine receptor CXCR4, interacting with its ligand CXCL12, plays a crucial role in tumor proliferation, metastasis, and treatment resistance. This study explores the therapeutic potential of engineered monomeric and dimerized CXCL12 variants (CXCL121 and CXCL122, respectively) in HNSCC and evaluates potential additive effects when combined with radiation therapy.Methods: Clinical HNSCC biopsies were evaluated for CXCR4 expression in both previously untreated and radiorecurrent disease. HNSCC cell lines were then treated with combinations of CXCL12 variants and radiotherapy and interrogated for proliferation, gene expression change, and underlying molecular mechanisms. In vivo studies evaluated the biodistribution of engineered CXCL12 and tested these treatments in humanized cell line‐derived xenograft (CDX) models.Results: CXCL122 significantly reduced HNSCC cell proliferation and enhanced the effects of radiotherapy, likely through biased agonism at the CXCR4 receptor and upregulation of the KISS1R pathway. In vivo, CXCL122 localized to tumor sites and augmented the effects of radiation to inhibit tumor growth.Conclusions: CXCL122, in combination with radiation, demonstrates potent anti‐tumor effects in HNSCC. These findings support further clinical investigation of CXCL122 to enhance the effects of radiotherapy.Keywords
Funding Information
- National Institutes of Health
- Cancer Center, Medical College of Wisconsin
- National Cancer Institute ((R01 CA226279))
This publication has 27 references indexed in Scilit:
- SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/Akt signaling pathwayJournal of Biosciences, 2024
- Chronic stress promotes an immunologic inflammatory state and head and neck cancer growth in a humanized murine modelHead & Neck, 2022
- The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent ChemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasisLife Sciences, 2020
- The role of kisspeptin system in cancer biologyCritical Reviews in Oncology/Hematology, 2019
- SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapyClinical and Translational Radiation Oncology, 2017
- Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathwaysProceedings of the National Academy of Sciences, 2011
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- CXCR4 antagonists: targeting the microenvironment in leukemia and other cancersLeukemia, 2008
- Involvement of chemokine receptors in breast cancer metastasisNature, 2001